Skip to main content

Table 5 TRAEs in 26 converted patients

From: Real-world practice of conversion surgery for unresectable hepatocellular carcinoma - a single center data of 26 consecutive patients

TRAEs

Any grade

   (n, %)

Grade1~2

   (n, %)

Grade≥3

  (n, %)

Hypertension

1 (3.8)

0 (0)

1 (3.8)

Decreased appetite

3 (11.5)

3 (11.5)

0 (0)

Abdominal pain

3 (11.5)

3 (11.5)

0 (0)

Nausea

2 (7.7)

2 (7.7)

0 (0)

Elevated alanine aminotransferase, ALT

16 (61.5)

12 (46.2)

4 (15.4)

Elevated aspartate aminotransferase, AST

19 (73.1)

13 (50)

6 (23.1)

Elevated blood bilirubin

13 (50)

12 (46.2)

1 (3.8)

Hypothyroidism

3 (11.5)

3 (11.5)

0 (0)

Palmar-plantar erythrodyses-thesia syndrome

2 (7.7)

2 (7.7)

0 (0)

Fatigue

1 (3.8)

1 (3.8)

0 (0)

Low leucocyte amount

3 (11.5)

2 (7.7)

1 (3.8)

Neutrocytopenia

1 (3.8)

1 (3.8)

0 (0)

Thrombocytopenia

7 (26.9)

5 (19.2)

2 (7.7)

Oral mucositis

1 (3.8)

0 (0)

1 (3.8)

Rash

1 (3.8)

1 (3.8)

0 (0)

ICIs-associated myocarditis

1 (3.8)

0 (0)

1 (3.8)

RCCEP

1 (3.8)

1 (3.8)

0 (0)

  1. TRAEs Treatment-related adverse events, ICIs Immune checkpoint inhibitors, RCCEP Reactive cutaneous capillary endothelial proliferation